Li Cuicui, Jin Kang
Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmacy, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Curr Med Chem. 2024;31(14):1839-1873. doi: 10.2174/0929867330666230426111157.
Cancer is increasingly recognized as one of the primary causes of death and has become a multifaceted global health issue. Modern medical science has made significant advancements in the diagnosis and therapy of cancer over the past decade. The detrimental side effects, lack of efficacy, and multidrug resistance of conventional cancer therapies have created an urgent need for novel anticancer therapeutics or treatments with low cytotoxicity and drug resistance. The pharmaceutical groups have recognized the crucial role that peptide therapeutic agents can play in addressing unsatisfied healthcare demands and how these become great supplements or even preferable alternatives to biological therapies and small molecules. Anticancer peptides, as a vibrant therapeutic strategy against various cancer cells, have demonstrated incredible anticancer potential due to high specificity and selectivity, low toxicity, and the ability to target the surface of traditional "undruggable" proteins. This review will provide the research progression of anticancer peptides, mainly focusing on the discovery and modifications along with the optimization and application of these peptides in clinical practice.
癌症日益被视为主要死因之一，并已成为一个多方面的全球健康问题。在过去十年中，现代医学科学在癌症的诊断和治疗方面取得了重大进展。传统癌症疗法的有害副作用、疗效不佳和多药耐药性，迫切需要新型抗癌疗法或低细胞毒性和耐药性的治疗方法。制药集团已经认识到肽治疗剂在满足未满足的医疗需求方面可以发挥的关键作用，以及这些肽如何成为生物疗法和小分子的重要补充甚至更优替代品。抗癌肽作为一种针对各种癌细胞的活跃治疗策略，由于其高特异性和选择性、低毒性以及靶向传统“不可成药”蛋白表面的能力，已展现出令人难以置信的抗癌潜力。本综述将介绍抗癌肽的研究进展，主要关注这些肽的发现、修饰以及在临床实践中的优化和应用。
